News headlines about WAVE Life Sciences (NASDAQ:WVE) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. WAVE Life Sciences earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.0843645536144 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

WVE has been the subject of several research analyst reports. Zacks Investment Research cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. ValuEngine cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Jefferies Group LLC restated a “buy” rating and issued a $42.00 target price on shares of WAVE Life Sciences in a report on Wednesday, April 26th. Finally, JMP Securities restated an “outperform” rating and issued a $40.00 target price on shares of WAVE Life Sciences in a report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. WAVE Life Sciences has an average rating of “Hold” and an average price target of $41.50.

Shares of WAVE Life Sciences (WVE) traded down 2.49% during mid-day trading on Friday, reaching $17.65. 32,855 shares of the company were exchanged. WAVE Life Sciences has a 12 month low of $15.15 and a 12 month high of $40.15. The company’s 50-day moving average is $18.75 and its 200 day moving average is $23.17. The firm’s market capitalization is $489.96 million.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.14. WAVE Life Sciences had a negative net margin of 3,375.12% and a negative return on equity of 55.19%. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.73 million. Analysts predict that WAVE Life Sciences will post ($3.70) EPS for the current year.

In other news, insider Michael A. Panzara sold 7,414 shares of the business’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the completion of the transaction, the insider now owns 15,336 shares of the company’s stock, valued at $255,651.12. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 53.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect WAVE Life Sciences (NASDAQ:WVE) Stock Price” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with's FREE daily email newsletter.